Publications by PD Dr. Berislav Bošnjak

Selected Publications

For a full list, go to https://orcid.org/0000-0003-3374-7488

2025

Liu X, Gutierrez Jauregui R, Lueder Y, Halle S, Ospina-Quintero L, Ritter C, Schimrock A, Willenzon S, Janssen A, Wagner K, Messerle M, Bošnjak B*, Förster R*. Protective function of ex vivo-expanded CD8 T cells in a mouse model of adoptive therapy for cytomegalovirus infection depends on integrin beta 1 but not CXCR3, CTLA4, or PD-1 expression. J Leukoc Biol 2025; 117(4): qiae256. (* authors equally contributed to the paper)
https://pubmed.ncbi.nlm.nih.gov/40276928/

2023

Bošnjak B*, Henze E*, Lueder Y, Do KTH, Rezalotfi A, Čuvalo B, Ritter C, Schimrock A, Willenzon S, Georgiev H, Fritz L, Galla M, Wagner K, Messerle M, Förster R. MCK2-mediated MCMV infection of macrophages and virus dissemination to the salivary gland depends on MHC class I molecules. Cell Rep 2023; 42(6): 112597. (* authors equally contributed to the paper)
https://pubmed.ncbi.nlm.nih.gov/37289588/

Bošnjak B*, Lueder Y*, Messerle M, Förster R. Imaging cytomegalovirus infection and ensuing immune responses. Curr Opin Immunol 2023; 82: 102307. (* authors equally contributed to the paper; review)
https://pubmed.ncbi.nlm.nih.gov/36996701/

2022

Bošnjak B, Do KTH, Förster R, Hammerschmidt SI. Imaging dendritic cell functions. Immunol. Rev. 2022 306, 137–163.
https://pubmed.ncbi.nlm.nih.gov/34859450/

Rezalotfi A, Fritz L, Förster R*, Bošnjak B*. Challenges of CRISPR-Based Gene Editing in Primary T Cells. Int. J. Mol. Sci. 2022 23, 1689. (* equally contributing corresponding authors)
https://pubmed.ncbi.nlm.nih.gov/35163611/

2021

Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B*, Förster R*, Behrens GMN*. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med. 2021 27, 1525–1529. (* equally contributing corresponding authors)
https://pubmed.ncbi.nlm.nih.gov/34262158/

Bošnjak B*, Odak I*, Barros-Martins J*, Sandrock I*, Hammerschmidt SI, Permanyer M, Patzer GE, Greorgiev H, Gutierrez Jauregui R, Tscherne A, Schwarz JH, Kalodimou G, Ssebyatika G, Ciurkiewicz M, Willenzon S, Bubke A, Ristenpart J, Ritter C, Tuchel T, Meyer zu Natrup C, Shin D-L, Clever S, Limpinsel L, Baumgärtner W, Krey T, Volz A, Sutter G, Förster R. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. 2021 Front. Immunol. 12, 1–18. (* authors equally contributed to the paper)
https://pubmed.ncbi.nlm.nih.gov/34858430/

Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey CR, Gödecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoeper MM, Behrens GMN, Pöhlmann S, Blasczyk R, Schulz TF, Förster R. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell. Mol. Immunol. 2021 18, 936–944.
https://pubmed.ncbi.nlm.nih.gov/33139905/